StockData
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL) stock

CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$333.25+1.09 (+0.33%)

Close on Nov 18, 2026Market cap $15.91BP/E –Yield –

Charles River Laboratories International operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Charles River Laboratories International's operating income for the twelve months ending Jun 27, 2026 was $90.14M, down 27.6% year over year. For fiscal 2025 it was $25.16M, down 88.9% from the year before. Over ten years it grew -19.0% a year on average. The highest annual figure on record is $650.98M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 27, 2025$25.16M-88.9%
FY2024Dec 28, 2024$227.35M-63.2%
FY2023Dec 30, 2023$617.26M-5.2%
FY2022Dec 31, 2022$650.98M+10.4%
FY2021Dec 25, 2021$589.86M+36.3%
FY2020Dec 26, 2020$432.73M+23.2%
FY2019Dec 28, 2019$351.15M+6.0%
FY2018Dec 29, 2018$331.38M+15.0%
FY2017Dec 30, 2017$288.28M+21.4%
FY2016Dec 31, 2016$237.55M+15.1%
FY2015Dec 26, 2015$206.45M+16.2%
FY2014Dec 27, 2014$177.67M+17.4%
FY2013Dec 28, 2013$151.40M-8.7%
FY2012Dec 29, 2012$165.77M-4.9%
FY2011Dec 31, 2011$174.31M–
FY2010Dec 25, 2010-$298.51M-276.0%
FY2009Dec 26, 2009$169.61M–
FY2008Dec 27, 2008-$451.84M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$119.89M+19.7%
Q1 FY2026Mar 28, 2026$119.90M+60.6%
Q4 FY2025Dec 27, 2025-$283.44M–
Q3 FY2025Sep 27, 2025$133.80M+14.0%
Q2 FY2025Jun 28, 2025$100.13M-34.0%
Q1 FY2025Mar 29, 2025$74.67M-40.7%
Q4 FY2024Dec 28, 2024-$167.69M-226.2%
Q3 FY2024Sep 28, 2024$117.41M-22.5%
Q2 FY2024Jun 29, 2024$151.65M-8.1%
Q1 FY2024Mar 30, 2024$125.98M-25.0%
Q4 FY2023Dec 30, 2023$132.92M-18.9%
Q3 FY2023Sep 30, 2023$151.50M+0.3%
Q2 FY2023Jul 1, 2023$164.95M-12.0%
Q1 FY2023Apr 1, 2023$167.89M+12.8%
Q4 FY2022Dec 31, 2022$163.81M-5.2%
Q3 FY2022Sep 24, 2022$150.98M-3.1%
Q2 FY2022Jun 25, 2022$187.41M+36.2%
Q1 FY2022Mar 26, 2022$148.78M+20.3%
Q4 FY2021Dec 25, 2021$172.81M+34.0%
Q3 FY2021Sep 25, 2021$155.80M+17.4%
Q2 FY2021Jun 26, 2021$137.55M+79.2%
Q1 FY2021Mar 27, 2021$123.70M+31.2%
Q4 FY2020Dec 26, 2020$128.93M+18.5%
Q3 FY2020Sep 26, 2020$132.75M+43.0%
Q2 FY2020Jun 27, 2020$76.77M-3.8%
Q1 FY2020Mar 28, 2020$94.28M+35.1%
Q4 FY2019Dec 28, 2019$108.79M+6.2%
Q3 FY2019Sep 28, 2019$92.80M+10.0%
Q2 FY2019Jun 29, 2019$79.77M+4.0%
Q1 FY2019Mar 30, 2019$69.79M+2.9%
Q4 FY2018Dec 29, 2018$102.48M+63.1%
Q3 FY2018Sep 29, 2018$84.36M+13.9%
Q2 FY2018Jun 30, 2018$76.71M-6.1%
Q1 FY2018Mar 31, 2018$67.83M-2.7%
Q4 FY2017Dec 30, 2017$62.83M-9.1%
Q3 FY2017Sep 30, 2017$74.06M+26.0%
Q2 FY2017Jul 1, 2017$81.69M–
Q1 FY2017Apr 1, 2017$69.71M–
Q4 FY2016Dec 31, 2016$69.09M–
Q3 FY2016Sep 24, 2016$58.80M–

More Charles River Laboratories International figures

See a number that looks wrong?